Table 5.
Results of ITS analysis for the change of volume, expenditures, and DDDc of policy-related antihypertensive drugs
| Volume | Expenditures | DDDc | ||||
|---|---|---|---|---|---|---|
| Coef. | 95 % CI | Coef. | 95 % CI | Coef. | 95 % CI | |
| Bid-winning drugs | ||||||
| Baseline change, β0 | 0.24 | (-0.35, 0.83) | 0.47 | (0.18, 0.77)** | 2.04 | (1.96, 2.12)*** |
| Baseline trend, β1 | 0.01 | (-0.07, 0.09) | 0.02 | (-0.02, 0.06) | -0.02 | (-0.03, -0.01)** |
| Level change, β2 | 3.12 | (2.14, 4.10)*** | 0.93 | (0.45, 1.42)** | -1.30 | (-1.43, -1.18)*** |
| Trend change, β3 | 0.13 | (-0.02, 0.28) | 0.01 | (-0.06, 0.09) | 0.01 | (-0.01, 0.03) |
| R2 | 0.94 | 0.85 | 0.99 | |||
| Durbin-Watson d | 2.12 | 2.11 | 1.91 | |||
| Non-winning drugs | ||||||
| Baseline change, β0 | 1.66 | (1.36, 1.96)*** | 5.39 | (4.40, 6.38)*** | 3.20 | (3.09, 3.30)*** |
| Baseline trend, β1 | 0.09 | (0.05, 0.13)*** | 0.26 | (0.13, 0.39)*** | -0.004 | (-0.02, 0.01) |
| Level change, β2 | -2.33 | (-2.83, -1.82)*** | -6.92 | (-8.57, -5.28)*** | 0.28 | (0.11, 0.46)** |
| Trend change, β3 | -0.11 | (-0.19, -0.03)** | -0.34 | (-0.59, -0.09)* | 0.01 | (-0.02, 0.03) |
| R2 | 0.92 | 0.91 | 0.65 | |||
| Durbin-Watson d | 2.20 | 2.11 | 2.00 | |||
| “4 + 7” List drugs | ||||||
| Baseline change, β0 | 1.97 | (1.19, 2.74)*** | 5.88 | (4.73, 7.02)*** | 3.06 | (2.89, 3.24)*** |
| Baseline trend, β1 | 0.09 | (-0.01, 0.19) | 0.28 | (0.13, 0.43)** | -0.01 | (-0.03, 0.02) |
| Level change, β2 | 0.95 | (-0.33, 2.23) | -5.96 | (-7.87, -4.04)*** | -1.94 | (-2.21, -1.66)*** |
| Trend change, β3 | 0.02 | (-0.18, 0.22) | -0.33 | (-0.62, -0.04)* | -0.04 | (-0.09, 0.002) |
| R2 | 0.74 | 0.84 | 0.98 | |||
| Durbin-Watson d | 2.15 | 2.15 | 1.96 | |||
| Alternative drugs | ||||||
| Baseline change, β0 | 3.91 | (3.11, 4.71)*** | 12.76 | (10.36, 15.17)*** | 3.24 | (3.18, 3.31)*** |
| Baseline trend, β1 | 0.16 | (0.05, 0.26)** | 0.41 | (0.10, 0.73)* | -0.02 | (-0.02, -0.01)** |
| Level change, β2 | -0.91 | (-2.24, 0.42) | -1.99 | (-5.99, 2.02) | 0.14 | (0.03, 0.25)* |
| Trend change, β3 | 0.01 | (-0.20, 0.21) | -0.01 | (-0.62, 0.60) | 0.00 | (-0.02, 0.01) |
| R2 | 0.62 | 0.56 | 0.59 | |||
| Durbin-Watson d | 2.25 | 2.18 | 2.03 | |||
|
Overall policy-related antihypertensive drugs |
||||||
| Baseline change, β0 | 5.85 | (4.49, 7.20)*** | 18.59 | (15.28, 21.90)*** | 3.18 | (3.09, 3.27)*** |
| Baseline trend, β1 | 0.25 | (0.07, 0.43)** | 0.70 | (0.26, 1.13)** | -0.01 | (-0.02, 0.00)* |
| Level change, β2 | -0.01 | (-2.26, 2.25) | -8.02 | (-13.54, -2.51)** | -0.78 | (-0.92, -0.63)*** |
| Trend change, β3 | 0.02 | (-0.33, 0.36) | -0.35 | (-1.19, 0.49) | -0.02 | (-0.04, 0.004) |
| R2 | 0.74 | 0.47 | 0.98 | |||
| Durbin-Watson d | 2.36 | 2.24 | 2.35 | |||
DDDc, Defined Daily Drug cost; CI, confidence interval